Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer

The results of a 2-year multicenter open randomized study

Keisei Anan, Shoshu Mitsuyama, Yasuhiro Yanagita, Morihiko Kimura, Hiroyoshi Doihara, Kansei Komaki, Mikihiro Kusama, Tadashi Ikeda

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The potential long-term adverse effects on quality of life have to be considered when selecting agents for adjuvant hormonal treatment for postmenopausal patients with estrogen receptor-positive breast cancer. We performed a 2-year multicenter randomized study to assess the differences in the time course effects between toremifene (TOR) and anastrozole (ANA) on serum lipid profiles and bone metabolism. This study assessed the serum levels of triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-1 (Apo A1), and apolipoprotein B (Apo B) as lipid profiles and bone-specific alkaline phosphatase (BAP) and the N-telopeptide of type-I collagen (NTX) as bone turnover markers in patients who received daily doses of 40 mg and 1 mg for TOR and ANA, respectively. A decreased serum level of TC, LDL-C, and Apo B was, respectively, observed at 6 months in 6.2, 12.9, and 13.8% of the patients who received TOR compared with the baseline. These decreases were maintained for at least 24 months. These lipid levels were not changed in those who received ANA. In the TOR patients, there was an increase in the serum level of HDL-C and Apo A1 at 6 months in 17.1 and 16.3%, respectively, which was maintained for at least 24 months, whereas these levels were almost stable in the patients who received ANA. Serum BAP decreased by 12.1% at 12 months and further decreased at 24 months and the serum NTX decreased by 22.0% at 6 months, which was maintained for at least 24 months in the patients who received TOR. In contrast, the serum BAP was increased by 26.0% at 6 months and by 29.2% at 12 months and the serum NTX increased by 21.3% at 24 months compared with baseline in those received ANA. However, the serum BAP increase was not significant at 24 months. TOR provides better effects than ANA in terms of lipid profiles and bone metabolism in postmenopausal females with early breast cancer.

Original languageEnglish
Pages (from-to)775-781
Number of pages7
JournalBreast Cancer Research and Treatment
Volume128
Issue number3
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Toremifene
Lipid Metabolism
Estrogen Receptors
Breast Neoplasms
Bone and Bones
Serum
Alkaline Phosphatase
Lipids
Apolipoprotein A-I
Apolipoproteins B
LDL Cholesterol
HDL Cholesterol
Cholesterol
anastrozole
Bone Remodeling
Collagen Type I
Multicenter Studies
Triglycerides
Quality of Life

Keywords

  • Adjuvant therapy
  • Bone-specific alkaline phosphatase
  • High-density lipoprotein cholesterol
  • Low-density lipoprotein cholesterol
  • N-telopeptide of type-I collagen
  • Postmenopausal breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer : The results of a 2-year multicenter open randomized study. / Anan, Keisei; Mitsuyama, Shoshu; Yanagita, Yasuhiro; Kimura, Morihiko; Doihara, Hiroyoshi; Komaki, Kansei; Kusama, Mikihiro; Ikeda, Tadashi.

In: Breast Cancer Research and Treatment, Vol. 128, No. 3, 08.2011, p. 775-781.

Research output: Contribution to journalArticle

@article{a80123e0d74e468c808157c72e7d6559,
title = "Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: The results of a 2-year multicenter open randomized study",
abstract = "The potential long-term adverse effects on quality of life have to be considered when selecting agents for adjuvant hormonal treatment for postmenopausal patients with estrogen receptor-positive breast cancer. We performed a 2-year multicenter randomized study to assess the differences in the time course effects between toremifene (TOR) and anastrozole (ANA) on serum lipid profiles and bone metabolism. This study assessed the serum levels of triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-1 (Apo A1), and apolipoprotein B (Apo B) as lipid profiles and bone-specific alkaline phosphatase (BAP) and the N-telopeptide of type-I collagen (NTX) as bone turnover markers in patients who received daily doses of 40 mg and 1 mg for TOR and ANA, respectively. A decreased serum level of TC, LDL-C, and Apo B was, respectively, observed at 6 months in 6.2, 12.9, and 13.8{\%} of the patients who received TOR compared with the baseline. These decreases were maintained for at least 24 months. These lipid levels were not changed in those who received ANA. In the TOR patients, there was an increase in the serum level of HDL-C and Apo A1 at 6 months in 17.1 and 16.3{\%}, respectively, which was maintained for at least 24 months, whereas these levels were almost stable in the patients who received ANA. Serum BAP decreased by 12.1{\%} at 12 months and further decreased at 24 months and the serum NTX decreased by 22.0{\%} at 6 months, which was maintained for at least 24 months in the patients who received TOR. In contrast, the serum BAP was increased by 26.0{\%} at 6 months and by 29.2{\%} at 12 months and the serum NTX increased by 21.3{\%} at 24 months compared with baseline in those received ANA. However, the serum BAP increase was not significant at 24 months. TOR provides better effects than ANA in terms of lipid profiles and bone metabolism in postmenopausal females with early breast cancer.",
keywords = "Adjuvant therapy, Bone-specific alkaline phosphatase, High-density lipoprotein cholesterol, Low-density lipoprotein cholesterol, N-telopeptide of type-I collagen, Postmenopausal breast cancer",
author = "Keisei Anan and Shoshu Mitsuyama and Yasuhiro Yanagita and Morihiko Kimura and Hiroyoshi Doihara and Kansei Komaki and Mikihiro Kusama and Tadashi Ikeda",
year = "2011",
month = "8",
doi = "10.1007/s10549-011-1608-x",
language = "English",
volume = "128",
pages = "775--781",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer

T2 - The results of a 2-year multicenter open randomized study

AU - Anan, Keisei

AU - Mitsuyama, Shoshu

AU - Yanagita, Yasuhiro

AU - Kimura, Morihiko

AU - Doihara, Hiroyoshi

AU - Komaki, Kansei

AU - Kusama, Mikihiro

AU - Ikeda, Tadashi

PY - 2011/8

Y1 - 2011/8

N2 - The potential long-term adverse effects on quality of life have to be considered when selecting agents for adjuvant hormonal treatment for postmenopausal patients with estrogen receptor-positive breast cancer. We performed a 2-year multicenter randomized study to assess the differences in the time course effects between toremifene (TOR) and anastrozole (ANA) on serum lipid profiles and bone metabolism. This study assessed the serum levels of triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-1 (Apo A1), and apolipoprotein B (Apo B) as lipid profiles and bone-specific alkaline phosphatase (BAP) and the N-telopeptide of type-I collagen (NTX) as bone turnover markers in patients who received daily doses of 40 mg and 1 mg for TOR and ANA, respectively. A decreased serum level of TC, LDL-C, and Apo B was, respectively, observed at 6 months in 6.2, 12.9, and 13.8% of the patients who received TOR compared with the baseline. These decreases were maintained for at least 24 months. These lipid levels were not changed in those who received ANA. In the TOR patients, there was an increase in the serum level of HDL-C and Apo A1 at 6 months in 17.1 and 16.3%, respectively, which was maintained for at least 24 months, whereas these levels were almost stable in the patients who received ANA. Serum BAP decreased by 12.1% at 12 months and further decreased at 24 months and the serum NTX decreased by 22.0% at 6 months, which was maintained for at least 24 months in the patients who received TOR. In contrast, the serum BAP was increased by 26.0% at 6 months and by 29.2% at 12 months and the serum NTX increased by 21.3% at 24 months compared with baseline in those received ANA. However, the serum BAP increase was not significant at 24 months. TOR provides better effects than ANA in terms of lipid profiles and bone metabolism in postmenopausal females with early breast cancer.

AB - The potential long-term adverse effects on quality of life have to be considered when selecting agents for adjuvant hormonal treatment for postmenopausal patients with estrogen receptor-positive breast cancer. We performed a 2-year multicenter randomized study to assess the differences in the time course effects between toremifene (TOR) and anastrozole (ANA) on serum lipid profiles and bone metabolism. This study assessed the serum levels of triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-1 (Apo A1), and apolipoprotein B (Apo B) as lipid profiles and bone-specific alkaline phosphatase (BAP) and the N-telopeptide of type-I collagen (NTX) as bone turnover markers in patients who received daily doses of 40 mg and 1 mg for TOR and ANA, respectively. A decreased serum level of TC, LDL-C, and Apo B was, respectively, observed at 6 months in 6.2, 12.9, and 13.8% of the patients who received TOR compared with the baseline. These decreases were maintained for at least 24 months. These lipid levels were not changed in those who received ANA. In the TOR patients, there was an increase in the serum level of HDL-C and Apo A1 at 6 months in 17.1 and 16.3%, respectively, which was maintained for at least 24 months, whereas these levels were almost stable in the patients who received ANA. Serum BAP decreased by 12.1% at 12 months and further decreased at 24 months and the serum NTX decreased by 22.0% at 6 months, which was maintained for at least 24 months in the patients who received TOR. In contrast, the serum BAP was increased by 26.0% at 6 months and by 29.2% at 12 months and the serum NTX increased by 21.3% at 24 months compared with baseline in those received ANA. However, the serum BAP increase was not significant at 24 months. TOR provides better effects than ANA in terms of lipid profiles and bone metabolism in postmenopausal females with early breast cancer.

KW - Adjuvant therapy

KW - Bone-specific alkaline phosphatase

KW - High-density lipoprotein cholesterol

KW - Low-density lipoprotein cholesterol

KW - N-telopeptide of type-I collagen

KW - Postmenopausal breast cancer

UR - http://www.scopus.com/inward/record.url?scp=79960843384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960843384&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1608-x

DO - 10.1007/s10549-011-1608-x

M3 - Article

VL - 128

SP - 775

EP - 781

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -